Company news

Verrica Pharmaceuticals Inc. news in 2023

Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.

View company

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

November 9, 2023

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

August 30, 2023

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

August 23, 2023

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

August 9, 2023

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 7, 2023

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting

August 2, 2023

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

July 25, 2023

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8: 30 am ET

July 23, 2023

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

July 20, 2023

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

May 30, 2023

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

May 9, 2023

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

May 8, 2023

Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma

April 11, 2023

Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

March 5, 2023

Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference

February 27, 2023

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

February 26, 2023

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

February 20, 2023

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

January 23, 2023

Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

January 3, 2023

Calls in 2023

Decks in 2023